Summit Biolabs

Harnessing the Power of
Saliva Liquid-Biopsy

Head and Neck Cancer

Coming soon...


Summit Biolabs has developed and launched COVIDFast(TM) tests for COVID-19
• Rapid, highly accurate, and low cost direct-to-PCR tests
• Laboratory developed tests (LDTs)
• Work with either swab or saliva sample types, and are named accordingly

• First and only direct-to-PCR nasal swab test for COVID-19
• Utilizes Summit’s proprietary Viral Transport Buffer to enable extraction-free analysis
• Increases sample throughput by 3x-5x versus typical extraction swab PCR tests
• Convenient, non-invasive nostril swab

• The most accurate direct-to-PCR saliva test for COVID-19
Convenient, non-invasive saliva collection process

Value of COVIDFast(TM) over typical extraction PCR tests
• Superior diagnostic test accuracy
• Semi-automated or automated test processing
• Significantly lower testing cost
• Faster test turnaround time and reporting for result

Summit Biolabs has also developed and launched VOCFast(TM) test for COVID-19 Variants of Concern (VOC)
• First proxy PCR test for rapid testing of COVID-19 VOC
• Works with either nasal swab or saliva samples
• No need for lengthy and costly next-generation sequencing

About Us

Summit Biolabs is harnessing the power of saliva-based diagnostics for COVID-19 and head & neck cancer.

An early-stage molecular diagnostics company, Summit Biolabs is pioneering early detection of head & neck cancer recurrence using a first of its kind saliva liquid-biopsy, HNKlear. HNKlear is a proprietary, non-invasive saliva test that provides more effective, more accurate, and earlier detection of head and neck cancer recurrence than traditional diagnostic methods. This novel approach has the potential to revolutionize head and neck cancer surveillance and improve patient outcomes.

Summit Biolabs is also leveraging its core competencies in saliva-based molecular diagnostics and viral nucleic acid detection to join the fight against COVID-19. Along with their clinical and laboratory partners, Summit Biolabs is developing the first comprehensive panel of highly-accurate saliva-based tests for COVID-19 infection, quantitation and immune response.

Leadership Team

Bob Blomquist
Chief Executive Officer

Shi-Long Lu, MD PhD
Profile: 16th Annual BioScience Colorado magazine (p.25)
President & Chief Scientific Officer, Founder

José Zevallos, MD MPH FACS
Chief Medical Officer

Brian L. Harry, MD PhD
Chief Laboratory Officer

Eva Yao, PhD
Chief Operating Officer

Brian Williams, CPA
Chief Financial Officer

Business Advisors

Stanley Lapidus
Serial Entrepreneur, Inventor, Educator

David Brunel
Serial Entrepreneur

Gilad Gordon, MD MBA
Expert on Clinical Trials for Drugs & Devices

Floyd Taub, MD
Serial Entrepreneur, Inventor

November 18, 2020
Summit Receives Investment from U. of Colorado Anschutz Medical Campus CDI Fund
Link PDF

November 9, 2020
Summit Biolabs Founder Dr. Shi-Long Lu Featured In CU Innovations 2020 Annual Report
Link (p.26-27) PDF

October 22, 2020
Summit Biolabs Commercializing Tests for Head and Neck Cancer Recurrence, COVID-19 ~ GenomeWeb Full Article
Link PDF

October 14, 2020
Summit, CCPM to Develop Saliva Tests for COVID, Head & Neck Cancer
Full Press Release

October 6, 2020
TiE Women of Denver "Walk n Talk" Interview of Summit
Event Announcement

October 2, 2020
Summit Biolabs Wins CBSA Innovation Forum 2020 Innovation Showcase Pitch Competition
Full Press Release

September 16, 2020
Summit Biolabs Selected to Receive Prestigious Investment from CDI Fund
Full Press Release

September 9, 2020
Summit Biolabs Selected to Present at the CBSA Innovation Forum on October 1, 2020
CBSA Innovation Forum 2020
LinkedIn Post

August 28, 2020
Summit Biolabs Wins TiE Women of Denver Virtual Pitch Competition 2020
Full Press Release
LinkedIn Post


Summit Biolabs Advanced Molecular Diagnostics Laboratory is CLIA-certified (#06D2213521).

Contact Us

Summit Biolabs, Inc.
2115 N. Scranton St., Suite 3040A
Aurora, Colorado 80045

Thank You

We will get back to you shortly.